No RCTs were found. A phase II open trial compared two doses (6-5 mg/m2/day and 650 mg/m2/day) of oral bexarotene in 58 patients with refractory stage IA-IIA CTCL.62 The optimal dose was 300 mg/m2/day in terms of response and tolerability. Objective responses of 20%, 54% and 67% were noted at the 6-5, 300 and 650 mg/m2/day doses, respectively. Rates of disease progression were 47%, 21% and 13%, respectively. Median duration of response at the highest dose level was 516 days. In late stages of disease (stage IIB-IVB) OR rates of 45% (at 300 mg/m2/day) and 55% (at doses >300 mg/m2/day) have been reported with a relapse rate of 36% and projected median duration of response of 299 days.63
Was this article helpful?
Do You Suffer From the Itching and Scaling of Psoriasis? Or the Chronic Agony of Psoriatic Arthritis? If so you are not ALONE! A whopping three percent of the world’s populations suffer from either condition! An incredible 56 million working hours are lost every year by psoriasis sufferers according to the National Psoriasis Foundation.